Translational Multimodality Neuroimaging.

Translational Multimodality Neuroimaging. Curr Drug Targets. 2017 Mar 15;: Authors: Sharma SK Abstract Recently high-resolution, noninvasive, multimodality in-vivo molecular imaging with PET, SPECT, CT and MRI, employing fusion algorithms has revolutionized personalized medicine. However, specific radiopharmaceuticals (RPs) for the accurate diagnosis and effective treatment of progressive neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, drug addiction, and other cognitive impairments still remain in developmental phase. Currently, multimodality fusion neuroimaging is utilized for the determination of: pharmacokinetics and pre-clinical development of radiopharmaceuticals (RPs); in-vivo monitoring of stem cell transplantation therapy; nicotinic acetylcholine receptors (nAChRs) investigations; and regional cerebral blood flow and glucose metabolism in cognitively-impaired subjects employing noninvasive microPET and nano-SPECT imaging. Furthermore, multimodality imaging is performed to detect CNS infections using 99mTc-HMPAO SPECT and 18F-FDG PET/CT. In this review, recent knowledge regarding multimodality fusion imaging is discussed with a primary emphasis on nanoSPECT/CT, PET-CT, and PET-MRI. Furthermore, limitations of individual imaging system are highlighted to emphasize the importance of complementary multimodality imaging for theranostic applications. Future developments in specific RPs will facilitate ...
Source: Current Drug Targets - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Targets Source Type: research